Phaseline

Companies › Portal Diabetes

Portal Diabetes: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Portal Insulin U-500 (PI-U500)
Insulin analog
INSPhase 1Type 1 Diabetes–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07341373Portal Insulin U-500 (PI-U500)Phase 1Type 1 DiabetesMetabolic and endocrineSep 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

INS (1)

Companies with the same targets

Elgan Pharma Gateway Institute for Brain Research Gan & Lee Pharmaceuticals.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.